Nicotine and fluoxetine induce arousing effects on sleep-wake cycle in antidepressive doses: a possible mechanism of antidepressant-like effects of nicotine

Pharmacology, Biochemistry, and Behavior
Gonzalo Vázquez-PalaciosHerlinda Bonilla-Jaime

Abstract

A number of studies have reported an association between smoking and depression, and several reports suggest that nicotine (NIC) may act as an antidepressant. The present study was designed to determine whether the effects of NIC on sleep-wake patterns in rats are similar to those of the antidepressant fluoxetine (FLX), a selective serotonin reuptake inhibitor. Male rats were chronically implanted with a standard set of electrodes for sleep recording. We compared the effects of antidepressive doses of NIC, FLX and the combination of both drugs on sleep-wake pattern in rats subjected to one day, one week and two weeks of administration, as well as after the withdrawal of the two-week treatment. The changes observed in our study in an 8-h sleep recording period during one day, one week and two weeks of NIC administration are very similar to those observed in the rats that received FLX, which led to a decrease in both slow wave sleep II and rapid eye movement (REM) sleep as a consequence of an increase in wakefulness. In addition, all treatments also induced a significant lengthening of REM sleep latency onset. These data suggest that the antidepressant-like action of NIC could be caused by its arousing properties.

References

May 1, 1975·Pharmacology, Biochemistry, and Behavior·J E Hubbard, R S Gohd
Jan 1, 1990·Neuroscience and Biobehavioral Reviews·G W VogelA Hennessey
Jul 17, 1990·European Journal of Pharmacology·Y ChaputR Andrade
Jul 31, 1990·Neuroscience Letters·J Velazquez-MoctezumaP J Shiromani
Jan 1, 1990·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·D McNamaraT T Soncrant
Dec 1, 1970·Shinrigaku kenkyu : The Japanese journal of psychology·E Takeuchi
Oct 29, 1965·Science·E F Domino, K I Yamamoto
Aug 1, 1995·Naunyn-Schmiedeberg's Archives of Pharmacology·E Le PoulL Lanfumey
Sep 1, 1994·International Clinical Psychopharmacology·V VasarJ Selvaratnam
Aug 1, 1994·American Journal of Respiratory and Critical Care Medicine·D G DavilaJ W Shepard
Jun 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C M DorseyS L Cunningham
Oct 21, 1996·Brain Research·J VazquezR Drucker-Colín
Mar 25, 1998·Neuroreport·J A HobsonE F Pace-Schott
Dec 9, 1998·European Journal of Pharmacology·S MihailescuR Drucker-Colín
Apr 2, 1999·Psychopharmacology·Y TizabiM A Kling
Apr 8, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M H TrivediH P Roffwarg
Aug 5, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·P Blier, C de Montigny
Aug 27, 1999·Psychopharmacology·R J Salin-PascualC Blanco-Centurion
Mar 25, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M R PicciottoV Zachariou
Apr 4, 2001·The European Journal of Neuroscience·P J KennyM Rattray
May 10, 2001·The International Journal of Neuropsychopharmacology·Klaus Peter Lesch, Armin Heils
Nov 10, 2001·Psychopharmacology·K Nakamura, Y Tanaka
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·Pallab SethSandra E File
Sep 6, 2003·Acta Psychiatrica Scandinavica. Supplementum·M BergerD Riemann
Jan 13, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Benoît Saint-MleuxMauro Serafin
Feb 3, 2004·Current Topics in Medicinal Chemistry·Paul NewhouseAlexandra Potter
May 29, 2004·Trends in Pharmacological Sciences·Federico Dajas-Bailador, Susan Wonnacott
Jun 25, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Clément LénaJoëlle Adrien
Jul 28, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Michael J BuckleyPeter Curzon
Aug 26, 2004·The International Journal of Neuropsychopharmacology·Jaime M Monti, Héctor Jantos
Oct 27, 2004·Medical Hypotheses·Leo Sher
Dec 22, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Gonzalo Vázquez-PalaciosJavier Velázquez-Moctezuma

❮ Previous
Next ❯

Citations

Apr 10, 2013·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Thomas J PayneMing D Li
May 31, 2014·Neurotoxicology·Neice Muller Xavier FariaVanessa Iribarrem Miranda
Feb 27, 2013·Cephalalgia : an International Journal of Headache·Keisuke SuzukiKoichi Hirata
Dec 18, 2020·Frontiers in Neuroscience·Anjum ParkarDinesh Pal
Jul 3, 2021·Neurotoxicology·Ana Laura Sica Cruzeiro SzortykaAnaclaudia Gastal Fassa

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Bernd FeigeMathias Berger
European Journal of Pharmacology
Magnus IvarssonPeter H Hutson
© 2022 Meta ULC. All rights reserved